532523:BOM
Biocon Ltd
351,25Â INR
arrow_upward
+0,06%(+0,20) 1G
14 ott, 15:30:00 GMT+5:30 · INR
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per 532523 in corso…
Apertura
352,80Â INR
Massimo
352,80Â INR
Minimo
346,95Â INR
Cap. mercato
571,07Â Mld
Vol. medio
717,26K
Volume
180,12K
Dividendo
0,14%
Dividendo trimestrale
0,12Â INR
Data di stacco dividendo
3 lug 2026
Rapporto P/E
103,99
Max 52 sett.
447,00Â INR
Min 52 sett.
337,95Â INR
Utili per azione
3,38Â INR
Azioni in circolazione
600,00Â Mln
N. di dipendenti
16K
Apertura
352,80Â INR
Massimo
352,80Â INR
Minimo
346,95Â INR
Cap. mercato
571,07Â Mld
Vol. medio
717,26K
Volume
180,12K
Dividendo
0,14%
Dividendo trimestrale
0,12Â INR
Data di stacco dividendo
3 lug 2026
Rapporto P/E
103,99
Max 52 sett.
447,00Â INR
Min 52 sett.
337,95Â INR
Utili per azione
3,38Â INR
Azioni in circolazione
600,00Â Mln
N. di dipendenti
16K
Articoli giornalistici
Da fonti web e partner giornalistici
BusinessLine
·
6 ore fa
Biocon gets launch clarity for breast cancer biosimilar after Genentech deal
Equitypandit
·
16 ore fa
Biocon Settles Patent Dispute With Genentech; Shares Down
Business Standard
·
17 ore fa
Biocon clears patent hurdle for breast cancer biosimilar Pebrilzo
Dalal Street Investment Journal
·
17 ore fa
Biocon settles Genentech disputes, secures 2027 EU and 2028 US launch window for Pebrilzo
Profilo
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Informazioni su Biocon Ltd
CEOShreehas P Tambe
Dipendenti16,4K
Data di fondazione29 nov 1978
SedeBangalore, Karnataka, India
Settore-
Sito webbiocon.com